Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/25/2018 |
| Start Date: | August 2006 |
| End Date: | October 2009 |
A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Primary objective is to determine the effectiveness of the combination of bortezomib and
doxorubicin in patients with metastatic breast cancer. The trial format is a single arm Phase
II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and with
doxorubicin IV on days 1 and 8 of a 21-day cycle.
doxorubicin in patients with metastatic breast cancer. The trial format is a single arm Phase
II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and with
doxorubicin IV on days 1 and 8 of a 21-day cycle.
Inclusion Criteria:
- Cytologically or histologically confirmed metastatic breast cancer
- Measurable or evaluable disease
- Age > 18, PS 0,1,2
- MUGA > 45%
- Received one or fewer chemotherapies or investigational regimens for metastatic
disease, no limit to the number of prior hormonal therapies. May have had single agent
Herceptin and/or Herceptin plus single-agent chemotx.
- Must meet designated laboratory criteria within 14 days of enrollment
Exclusion Criteria:
- Doxorubicin for metatstatic disease.
- Pregnant or lactating.
- Active infections, no myocardial infarction within 2 months of enrollment.
- Investigational drugs within 14 days of enrollment.
- Chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within 4
weeks of enrollment.
- Neuropathy that is > grade 2.
- Active brain mets.
- Hypersensitivity to bortezomib, boron, or mannitol.
We found this trial at
1
site
Click here to add this to my saved trials
